ArticleLeukemia research reports2026
Mixed-phenotype acute leukemia: Flow cytometric analysis in a tertiary care center of Bangladesh.
Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mixed-phenotype acute leukemia (MPAL) is a rare but difficult to treat hematologic malignancy. Methods: flow cytometry immunophenotyping method was used in EDTA bone marrow and/or peripheral blood taken from all consecutive morphologically diagnosed acute leukemia (AL) patients from November 2015 to December 2019. Results: Among 616 consecutive AL cases diagnosed and evaluated during this period, 22(3.57%) patients with MPAL were identified fulfilling WHO 2008 criteria for immunophenotypic characteristics of AL. Fifteen (68.2%) cases were diagnosed as B/myeloid, 5(22.72%) as T/myeloid and 2 (9.1%) as B/T MPAL. Morphologically diagnosed 15 (68.2%) AML cases were immunophenotypically B/Myeloid MPAL (12/15) and 3/15 cases were T/Myeloid MPAL. Morphologically 7 (31.8%) were ALL of which immunophenotypically 3/7 cases were B/Myeloid MPAL, 2/7 cases were T/Myeloid MPAL and 2/7 were B/T MPAL. Conclusion: Multiparametric flow cytometry using comprehensive panel of monoclonal antibodies is a valuable tool to diagnose MPAL known to have a poor outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.